News

Press Release: Elucid Bioimaging Announces Initial Q-CAMP CT Study Results Exceed Expectations

September 18, 2017
Wenham, Massachusetts – Elucid Bioimaging is pleased to announce that the lipid necrotic core, calcification, and plaque matrix objectives of its Q-CAMP study (NCT02143102) have been met. Elucid’s vascuCAP® software analysis of carotid CT Angiography (CTA) exceeded company expectations with its high correlation and low bias in its measurements of lipid rich necrotic core (LRNC),… View Article

Oral Presentation by Dr. Ajay Gupta, Weill Cornell Medical College, “SEMI-AUTOMATED DETECTION OF HIGH-RISK ATHEROSCLEROTIC CAROTID ARTERY PLAQUE FEATURES FROM COMPUTED TOMOGRAPHY ANGIOGRAPHY”, May 25 2017 – 26th European Stroke Conference, Berlin, Germany

May 25, 2017

Elucid Bioimaging Inc, announced today that it has received FDA 510(k) clearance to market its vascuCAP software (K163071) for evaluating CT images of patients with atherosclerosis.

May 25, 2017
May 25th, 2017 Wenham Massachusetts – Elucid Bioimaging Inc, announced today that it has received FDA 510(k) clearance to market its vascuCAP software (K163071) for evaluating CT images of patients with atherosclerosis. “This is a major milestone in the Elucid’s commercialization program”, remarked John Garber, Chief Executive Officer, “our visualization and measurement tools will be… View Article

Elucid Bioimaging is pleased to announce that they have met their recruiting targets for the Q-CAMP study

February 22, 2017
Wenham, MA–(BUSINESS WIRE) Elucid Bioimaging is pleased to announce that they have met their recruiting targets for the Q-CAMP study, enrollment has been completed and preliminary results will be announced in early June. Elucid started the Non-invasive Computer-Aided Phenotyping of Vasculopathy (Q-CAMP) study in 2014. Q-CAMP is a cross-sectional study of patients undergoing endarterectomy of… View Article

John Garber promoted to CEO of Elucid Bioimaging

February 13, 2017
February 10, 2017 Wenham, MA–(BUSINESS WIRE) The Board of Directors of Elucid Bioimaging announce that they have promoted John Garber to Chief Executive Officer, effective February 14, 2017. John’s mission will be the commercial launch of Elucid’s imaging biomarkers business and its expansion into the immune oncology space. As of this date, Elucid’s founder, Andrew… View Article

Elucid BioImaging Expands Executive Team with Appointment of John Garber

January 16, 2017
Wenham, MA (January 12th, 2017) — Elucid Bioimaging, Inc. (“Elucid”), a leader in quantitative medical imaging, is proud to announce the expansion of its executive team with the appointment of John T Garber, MBA, as Vice President of Sales and Business Development. John will strengthen Elucid’s operations and executive management and lead commercialization of their… View Article